MCID: EXC002
MIFTS: 42

Exocrine Pancreatic Insufficiency

Categories: Endocrine diseases

Aliases & Classifications for Exocrine Pancreatic Insufficiency

MalaCards integrated aliases for Exocrine Pancreatic Insufficiency:

Name: Exocrine Pancreatic Insufficiency 38 12 29 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:13316
MeSH 42 D010188
NCIt 47 C84316
SNOMED-CT 64 47367009
UMLS 69 C0267963

Summaries for Exocrine Pancreatic Insufficiency

MalaCards based summary : Exocrine Pancreatic Insufficiency is related to exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis and shwachman-diamond syndrome. An important gene associated with Exocrine Pancreatic Insufficiency is COX4I2 (Cytochrome C Oxidase Subunit 4I2), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Pancreatic secretion. The drugs Pancrelipase and Nitazoxanide have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, testes and pancreas, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Wikipedia : 72 Exocrine pancreatic insufficiency (EPI) is the inability to properly digest food due to a lack of... more...

Related Diseases for Exocrine Pancreatic Insufficiency

Diseases related to Exocrine Pancreatic Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
id Related Disease Score Top Affiliating Genes
1 exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis 12.5
2 shwachman-diamond syndrome 11.6
3 johanson-blizzard syndrome 11.4
4 pancreatic agenesis 1 11.0
5 pancreatic agenesis 2 11.0
6 pancreatitis 11.0
7 cystic fibrosis 10.5
8 inclusion body myopathy with paget disease of bone and frontotemporal dementia 10.3 PDX1 PTF1A
9 pulmonary venoocclusive disease 2 10.2 CFTR UBR1
10 gastrointestinal adenoma 10.2 CCK SCT
11 tricuspid valve stenosis 10.2 CCK SCT
12 tamoxifen-related endometrial lesion 10.2 CCK SCT
13 cirrhotic cardiomyopathy 10.2 CFTR SCT
14 bile duct cystadenocarcinoma 10.2 CCK SCT
15 iris mixed cell melanoma 10.1 CCK SCT
16 male reproductive system disease 10.1 CCK SCT
17 diaphanospondylodysostosis 10.1 PDX1 PTF1A
18 duodenitis 10.1
19 steatorrhea 10.1
20 chondroma 10.1 CCK SCT
21 distal muscular dystrophy 10.0 PDX1 PTF1A
22 retinal vascular occlusion 9.9 CCK SCT
23 ichthyosis 9.9
24 dysostosis 9.9
25 neutropenia 9.9
26 somatostatinoma 9.9
27 celiac disease 9.9
28 dwarfism 9.9
29 mandibular cancer 9.9 CCK CCKAR
30 dermatomyositis 9.8 CCK CCKAR
31 anorexia nervosa 9.8
32 addison's disease 9.8
33 hyperostosis 9.8
34 fabry disease 9.8
35 adenocarcinoma 9.8
36 calvarial hyperostosis 9.8
37 cutis laxa 9.8
38 autoimmune hepatitis 9.8
39 lactic acidosis 9.8
40 diabetic neuropathy 9.8
41 gastritis 9.8
42 hepatitis 9.8
43 liver disease 9.8
44 thyroiditis 9.8
45 obesity 9.8
46 duodenal somatostatinoma 9.8
47 netherton syndrome 9.8
48 neuropathy 9.8
49 tropical sprue 9.8
50 atrophic gastritis 9.8

Graphical network of the top 20 diseases related to Exocrine Pancreatic Insufficiency:



Diseases related to Exocrine Pancreatic Insufficiency

Symptoms & Phenotypes for Exocrine Pancreatic Insufficiency

MGI Mouse Phenotypes related to Exocrine Pancreatic Insufficiency:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.8 CCKAR CFTR PDX1 PNLIP PTF1A UBR1
2 endocrine/exocrine gland MP:0005379 9.73 CCK CCKAR CFTR PDX1 PTF1A UBR1
3 growth/size/body region MP:0005378 9.7 CCKAR CFTR COX4I2 PDX1 PNLIP PTF1A
4 homeostasis/metabolism MP:0005376 9.56 CCK CCKAR CFTR COX4I2 PDX1 PNLIP
5 liver/biliary system MP:0005370 9.02 CCKAR CFTR PDX1 PNLIP PTF1A

Drugs & Therapeutics for Exocrine Pancreatic Insufficiency

Drugs for Exocrine Pancreatic Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved Phase 4,Phase 2,Phase 3,Phase 1 53608-75-6
2
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
3 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
4 pancreatin Phase 4,Phase 2,Phase 3,Phase 1
5 Anti-Infective Agents Phase 4,Phase 2,Phase 3
6 Antiparasitic Agents Phase 4
7 Bifidobacterium Nutraceutical Phase 4
8
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
9
Busulfan Approved, Investigational Phase 2, Phase 3, Early Phase 1 55-98-1 2478
10
Fludarabine Approved Phase 2, Phase 3, Early Phase 1 21679-14-1, 75607-67-9 30751
11
Vidarabine Approved Phase 2, Phase 3 24356-66-9 32326 21704
12
alemtuzumab Approved, Investigational Phase 2, Phase 3,Early Phase 1 216503-57-0
13
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
14
Lenograstim Approved Phase 2, Phase 3 135968-09-1
15 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
16 Antacids Phase 3
17 Anti-Ulcer Agents Phase 3
18
Proton pump inhibitors Phase 3
19 Alkylating Agents Phase 2, Phase 3
20 Antilymphocyte Serum Phase 2, Phase 3
21 Antimetabolites Phase 2, Phase 3
22 Antimetabolites, Antineoplastic Phase 2, Phase 3
23 Antiviral Agents Phase 2, Phase 3
24 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
25 Antirheumatic Agents Phase 2, Phase 3,Phase 1
26 Adjuvants, Immunologic Phase 2, Phase 3
27
Secretin Approved, Investigational Phase 2 108153-74-8
28
Benzocaine Approved Phase 2 1994-09-7, 94-09-7 2337
29
Selenium Approved, Vet_approved Phase 2 7782-49-2
30
Zinc Approved Phase 2 7440-66-6 32051 23994
31
Cefazolin Approved Phase 2 25953-19-9 656510 33255
32
Dalteparin Approved Phase 2 9005-49-6
33
Heparin Approved, Investigational Phase 2 9005-49-6 772 46507594
34
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
35
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
36
Melphalan Approved Phase 2,Early Phase 1 148-82-3 4053 460612
37
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
38
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
39
Mechlorethamine Approved Phase 2 51-75-2 4033
40
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
41
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
42
Choline Approved, Nutraceutical Phase 2 62-49-7 305
43 tannic acid Approved, Nutraceutical Phase 2
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
46
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
47 Bile Acids and Salts Phase 2
48 Hypolipidemic Agents Phase 2
49 Lipid Regulating Agents Phase 2
50 Nootropic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 99)

id Name Status NCT ID Phase Drugs
1 Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT01327703 Phase 4 Panzytrat® 25,000;Kreon® 25,000
2 PR-018: An Open-Label, Safety Extension of Study PR-011 Completed NCT01131507 Phase 4 EUR-1008 (APT-1008)
3 A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age Completed NCT01100606 Phase 4 EUR-1008 (APT-1008);EUR-1008 (APT-1008)
4 Creon After Pancreatic Surgery Completed NCT00535756 Phase 4 Creon;Placebo
5 Enzyme Suppletion in Exocrine Pancreatic Dysfunction Completed NCT01430234 Phase 4 Panzytrat 25.000 FIP-E units of Lipase
6 Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea Completed NCT00572975 Phase 4
7 Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis Completed NCT00957151 Phase 4 Creon
8 Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Completed NCT01641341 Phase 4 Bifidobacterium infantis;Pancrelipase;Nitazoxanide;Placebo
9 EASY: Extended Access to Sollpura Over Years Recruiting NCT02823964 Phase 4 Liprotamase
10 Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase Terminated NCT01865695 Phase 4 Creon
11 Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control Terminated NCT00744250 Phase 4 Pancrelipase
12 A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 Withdrawn NCT02009410 Phase 4 Creon;Creon 25000 matching Placebo
13 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
14 Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency Unknown status NCT01012908 Phase 2, Phase 3
15 Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis. Completed NCT01641393 Phase 3 EUR-1008 25,000 Units;Kreon 25,000 Units
16 Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT00449878 Phase 3 Liprotamase;Placebo
17 Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00981214 Phase 3 EUR-1008 (APT-1008)
18 Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00297167 Phase 3 EUR-1008 (APT-1008);Placebo;Placebo;EUR-1008 (APT-1008)
19 A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency Completed NCT00662675 Phase 3 Pancrease MT 10.5, or MT 21;Placebo for Pancrease MT 10.5 or MT 21
20 A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI) Completed NCT00788593 Phase 3 Placebo;EUR-1008 (APT-1008) High Dose;EUR-1008 (APT-1008) Low Dose
21 A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency Completed NCT00400842 Phase 3 SA-001;SA-001;Placebo
22 Open-Label Phase III Long-Term Safety Trial of Liprotamase Completed NCT00449904 Phase 3 Liprotamase
23 Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI) Completed NCT00408317 Phase 3 Ultrase® MT20;Placebo
24 A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy Completed NCT00414908 Phase 3 Pancrelipase delayed release capsule;Placebo Comparator
25 Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT00775528 Phase 3 Pancrelipase Delayed Release
26 Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF) Completed NCT00690820 Phase 3 Pancrelipase Delayed Release;Placebo Comparator
27 SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis Completed NCT02734810 Phase 3 Liprotamase Powder for Oral Solution
28 A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency Completed NCT00401076 Phase 3 SA-001
29 Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency Completed NCT01747330 Phase 3 Pancreatin
30 Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis Completed NCT00705978 Phase 3 Pancreatin;Placebo
31 SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis Completed NCT02279498 Phase 3 Liprotamase;porcine (pig) PERT
32 Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT00510484 Phase 3 Pancrelipase Delayed Release;Placebo Comparator
33 Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea Completed NCT00559364 Phase 3 Viokase® 16;Placebo;Proton pump inhibitor (PPI);Omeprazole
34 A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT02137382 Phase 3 Creon®;Creon N
35 Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) Completed NCT00513682 Phase 3 Ultrase® MT20
36 Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis Completed NCT00432861 Phase 3 PANCRECARB® (pancrelipase);Placebo
37 Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF) Completed NCT00880100 Phase 3 Ultrase® MT12
38 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
39 RESULT: Reliable, Emergent Solution Using Liprotamase Treatment Recruiting NCT03051490 Phase 3 Liprotamase;porcine PERT
40 Stem Cell Transplant for Hemoglobinopathy Active, not recruiting NCT00176852 Phase 2, Phase 3 Busulfan, Fludarabine, ATG, TLI;Busulfan, Cyclophosphamide, ATG, GCSF;Campath, Fludarabine, Cyclophosphamide
41 Phase III ALTU-135 CP Safety Trial Terminated NCT00500084 Phase 3 Liprotamase
42 Effectiveness of Pancreatic Enzymes in Patients Pancreatic Insufficient: Comparison of Two Drugs Withdrawn NCT01228643 Phase 3
43 Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT01710644 Phase 1, Phase 2 Burlulipase;Placebo (Caramel in sterile water)
44 Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT02415959 Phase 2 Creon IR;Creon® (DR/GR)
45 Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency Completed NCT00095732 Phase 2 Liprotamase;Placebo
46 An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI) Completed NCT00559052 Phase 2 VIOKASE 16
47 Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency Completed NCT00743483 Phase 2 rhBSSL
48 A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI Completed NCT02370537 Phase 2 Epanova® (omega-3 carboxylic acids);Omacor® (omega-3-acid ethyl esters)
49 BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency Completed NCT01259544 Phase 2 benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala);benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
50 Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI Completed NCT00406536 Phase 2

Search NIH Clinical Center for Exocrine Pancreatic Insufficiency

Cochrane evidence based reviews: exocrine pancreatic insufficiency

Genetic Tests for Exocrine Pancreatic Insufficiency

Genetic tests related to Exocrine Pancreatic Insufficiency:

id Genetic test Affiliating Genes
1 Exocrine Pancreatic Insufficiency 29

Anatomical Context for Exocrine Pancreatic Insufficiency

MalaCards organs/tissues related to Exocrine Pancreatic Insufficiency:

39
Testes, Pancreas, Bone, Liver, Bone Marrow, Small Intestine, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Exocrine Pancreatic Insufficiency:
id Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells Potential therapeutic candidate, affected by disease

Publications for Exocrine Pancreatic Insufficiency

Articles related to Exocrine Pancreatic Insufficiency:

(show top 50) (show all 271)
id Title Authors Year
1
Exocrine pancreatic insufficiency is common in people living with HIV on effective antiretroviral therapy. ( 28838283 )
2017
2
Oxalate nephropathy presenting in exocrine pancreatic insufficiency. ( 28685941 )
2017
3
Common clinical features of CF (respiratory disease and exocrine pancreatic insufficiency). ( 28554722 )
2017
4
Systematic Review of Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer. ( 28315875 )
2017
5
Severe infantile isolated exocrine pancreatic insufficiency caused by the complete functional loss of the SPINK1 gene. ( 28945313 )
2017
6
Options for addressing exocrine pancreatic insufficiency in patients receiving enteral nutrition supplementation. ( 28727476 )
2017
7
Alzheimer's disease and other neurodegenerative diseases may be due to nutritional deficiencies secondary to unrecognized exocrine pancreatic insufficiency. ( 28478840 )
2017
8
Mutations in EFL1, an SBDS partner, are associated with infantile pancytopenia, exocrine pancreatic insufficiency and skeletal anomalies in aShwachman-Diamond like syndrome. ( 28331068 )
2017
9
A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities. ( 28727474 )
2017
10
The fecal microbiome of dogs with exocrine pancreatic insufficiency. ( 28223257 )
2017
11
Diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis: (13)C-Mixed Triglyceride Breath Test versus Fecal Elastase: Methodological issues. ( 28462863 )
2017
12
Prevalence of exocrine pancreatic insufficiency in patients with chronic pancreatitis without follow-up. PANCR-EVOL Study. ( 28935122 )
2017
13
Practical guide to exocrine pancreatic insufficiency - Breaking the myths. ( 28183317 )
2017
14
Diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis: (13)C-Mixed Triglyceride Breath Test versus Fecal Elastase. ( 28291656 )
2017
15
Response to "Diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis: (13)C-mixed Triglyceride Breath Test versus Fecal Elastase: Methodological issues". ( 28566224 )
2017
16
Novel ciliate lipases for enzyme replacement during exocrine pancreatic insufficiency. ( 27518039 )
2016
17
Applicability of a checklist for the diagnosis and treatment of severe exocrine pancreatic insufficiency. A survey on the management of pancreatic maldigestion in Italy. ( 27309260 )
2016
18
Challenges and Updates in the Management of Exocrine Pancreatic Insufficiency. ( 26658035 )
2016
19
Oral Supplementation with a Special Additive of Retinyl Palmitate and Alpha Tocopherol Reduces Growth Retardation in Young Pancreatic Duct Ligated Pigs Used as a Model for Children Suffering from Exocrine Pancreatic Insufficiency. ( 27690005 )
2016
20
Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. ( 27045859 )
2016
21
Lipomatous pseudohypertrophy of pancreas with coexisting chronic calcific pancreatitis leading to malabsorption due to exocrine pancreatic insufficiency. ( 28050116 )
2016
22
Rapid maxillary expansion in a pediatric patient with exocrine pancreatic insufficiency. ( 26943081 )
2016
23
Both Exocrine Pancreatic Insufficiency and Signs of Pancreatic Inflammation Are Prevalent in Children with Complicated Severe Acute Malnutrition: An Observational Study. ( 27178623 )
2016
24
Feline Exocrine Pancreatic Insufficiency: A Retrospective Study of 150 Cases. ( 27641602 )
2016
25
Exocrine Pancreatic Insufficiency. ( 26834230 )
2016
26
Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial. ( 27297209 )
2016
27
Atrophic Exocrine Pancreatic Insufficiency Associated with Anti-PD1 Therapy. ( 27864215 )
2016
28
Exocrine pancreatic insufficiency in a child with Netherton syndrome. ( 26986028 )
2016
29
Exocrine pancreatic insufficiency in diabetic patients: prevalence, mechanisms, and treatment. ( 25892991 )
2015
30
Exocrine pancreatic insufficiency, MRI of the pancreas and serum nutritional markers in patients with coeliac disease. ( 26253920 )
2015
31
Romanian Guidelines on the diagnosis and treatment of exocrine pancreatic insufficiency. ( 25822444 )
2015
32
Juvenile Diabetes Mellitus and Concurrent Exocrine Pancreatic Insufficiency in a Labrador Retriever: Long-Term Management. ( 26535463 )
2015
33
Diagnosis of Exocrine Pancreatic Insufficiency. ( 26077487 )
2015
34
Exocrine Pancreatic Insufficiency after Roux-en-Y gastric bypass. ( 26965152 )
2015
35
Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with Fabry disease. ( 25835592 )
2015
36
Association of DLA-DQB1 alleles with exocrine pancreatic insufficiency in Pembroke Welsh Corgis. ( 26095904 )
2015
37
Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus. ( 26495784 )
2015
38
Comparison of fecal elastase 1 for exocrine pancreatic insufficiency evaluation between ex-alcoholics and chronic pancreatitis patients. ( 25591157 )
2014
39
Prevalence of exocrine pancreatic insufficiency in type 2 diabetes mellitus with poor glycemic control. ( 25278304 )
2014
40
Exocrine pancreatic insufficiency and chronic pancreatitis in chronic alcoholic liver disease: coincidence or shared toxicity? ( 24713840 )
2014
41
Safety and efficacy of CreonAr Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis. ( 25066363 )
2014
42
Johanson-Blizzard syndrome: expanding the phenotype of exocrine pancreatic insufficiency. ( 25076350 )
2014
43
A piglet with surgically induced exocrine pancreatic insufficiency as an animal model of newborns to study fat digestion. ( 25348808 )
2014
44
Long-Term Experience With ZENPEP in Infants With Exocrine Pancreatic Insufficiency Associated With Cystic Fibrosis. ( 25050848 )
2014
45
Pancreatic enzyme replacement therapy in patients with exocrine pancreatic insufficiency due to chronic pancreatitis: a 1-year disease management study on symptom control and quality of life. ( 24717829 )
2014
46
Case report of exocrine pancreatic insufficiency in two palliative care patients. ( 24699789 )
2014
47
Recovery from exocrine pancreatic insufficiency in a patient with fulminant type 1 diabetes. ( 23448767 )
2013
48
Screening and risk factors of exocrine pancreatic insufficiency in critically ill adult patients receiving enteral nutrition. ( 23924602 )
2013
49
Biallelic PDX1 (insulin promoter factor 1) mutations causing neonatal diabetes without exocrine pancreatic insufficiency. ( 23320570 )
2013
50
CTLA-4 +49 and TNF-alpha-308 gene polymorphisms in celiac patients with exocrine pancreatic insufficiency. ( 24611333 )
2013

Variations for Exocrine Pancreatic Insufficiency

Expression for Exocrine Pancreatic Insufficiency

Search GEO for disease gene expression data for Exocrine Pancreatic Insufficiency.

Pathways for Exocrine Pancreatic Insufficiency

Pathways related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.46 CFTR PDX1 PTF1A
2 11.11 CCKAR CFTR PNLIP
3 9.47 CCK SCT

GO Terms for Exocrine Pancreatic Insufficiency

Biological processes related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 generation of precursor metabolites and energy GO:0006091 9.26 COX4I2 PDX1
2 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.16 CFTR PDX1
3 pancreas development GO:0031016 8.96 PDX1 PTF1A
4 exocrine pancreas development GO:0031017 8.62 PDX1 PTF1A

Sources for Exocrine Pancreatic Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....